Caricamento...
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
Chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) continues to make its way in the treatment of B-cell lymphomas. Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma. While its prognosis is usually good, the disease is considered incurable an...
Salvato in:
| Pubblicato in: | Ther Adv Hematol |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8165824/ https://ncbi.nlm.nih.gov/pubmed/34104371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20406207211017788 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|